Amgen Reports Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Amgen announced positive topline results from a Phase 3 study of its drug candidate, dazodalibep, for treating moderate-to-severe systemic Sjögren's disease. The results indicate that dazodalibep succeeded in the trial, following its acquisition in Amgen's buyout of Horizon Therapeutics.
The company is optimistic about the implications of these results for patients suffering from this autoimmune condition, which can cause significant discomfort and complications. This development marks a significant milestone for Amgen as it expands its portfolio in the autoimmune disease space.
Sources
Every quote below is verbatim from the article it is attributed to.
“AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE”
SEC Filing — AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE“<figure><div><img”
biopharma dive — Amgen reports a Phase 3 win with Sjögren’s drug candidate